- Home
- IBRX vs GATX Comparison
IBRX vs GATX Comparison
Compare IBRX & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | GATX |
|---|---|---|
| Founded | 2014 | 1898 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IBRX | GATX |
|---|---|---|
| Price | $8.58 | $191.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $11.80 | ★ $205.00 |
| AVG Volume (30 Days) | ★ 32.9M | 208.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $680.06 | $11.70 |
| Revenue Next Year | $90.34 | $37.38 |
| P/E Ratio | ★ N/A | $22.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $139.44 |
| 52 Week High | $8.28 | $194.80 |
Technical Indicators
Market Signals| Indicator | IBRX | GATX |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 70.00 |
| Support Level | $5.93 | $188.94 |
| Resistance Level | $7.30 | $192.88 |
| Average True Range (ATR) | 0.81 | 3.40 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 96.61 | 78.53 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.